Controversies in Breast Cancer: Adjuvant and Neoadjuvant Therapy 2008

Physicians' Education Resource
Last Modified: June 1, 2008

Share article


Conference Dates: October 3-5, 2008
Conference Location: New York, NY

Sponsoring Group: Physicians' Education Resource

Conference Web Page URL: http://www.cancerconferences.com/breast_cancer/adjuvant_1008_1102027/index.php

Topics Covered: The Controversies in Breast Cancer: Adjuvant and Neoadjuvant Therapy 2008 3-day congress is dedicated to an in-depth discussion of the emerging data that underlie optimal adjuvant and neoadjuvant breast cancer therapy, with a particular focus on data that impart an understanding of the biologic bases and natural history of the breast cancer subtypes. A significant emphasis on case discussion and management of patients with early-stage and locally advanced breast cancer will provide a forum to discuss and debate the controversies and practical applicability of the evolving clinical trial findings. The congress will address new data that influence practice in multidisciplinary areas of early breast cancer care, including pathology, breast imaging, breast cancer genetics and risk reduction, surgery, radiation therapy, and systemic therapy. The presentation and discussion of prognostic and predictive biomarkers will be a major theme of the congress to reflect the emerging issues that arise when oncologists strive to match the best therapy to the right patient. The congress will include lectures and case presentations, with a detailed discussion of diagnostic and treatment options as well as a point-counterpoint debate on controversial topics. Small-group breakout sessions with the faculty will be conducted for more in-depth discussion of controversial patient cases and topics. Participants will have the opportunity to critically review existing clinical trial data on adjuvant and neoadjuvant therapies and evaluate the application of these data to the ongoing management of patients with breast cancer through case discussions, panel discussions, and participant-directed discussion of patient-management dilemmas. The purpose of this congress is to provide an update on the latest advances in adjuvant and neoadjuvant therapy for breast cancer, addressing key areas of controversy.

At the conclusion of this symposium, you should be able to: Discuss the recent clinical trial data that provide the underpinnings for state-of-the-art adjuvant and neoadjuvant systemic therapy for breast cancer Review and debate the clinical utility and implications of novel genomic and pathologic diagnostic tools to subset breast cancer Evaluate novel cytotoxic and biologic agents and their utility in neoadjuvant or adjuvant regimens Analyze the optimal ability of adjuvant chemotherapy by breast cancer subtype Apply the available data toward an understanding of the optimal choice and duration of endocrine therapy Describe the principles of state-of-the-art imaging and surgical techniques as well as radiation therapy and apply them to the treatment of patients with breast cancer Review new diagnostic and management insights into hereditary breast cancers Review the latest data on preoperative therapies and surgical and radiotherapy management strategies

Who Should Attend: This educational program is designed to be of high clinical utility to medical, surgical, and radiation oncologists practicing in the community or academic institutions. Oncology fellows, oncology nurses, oncology physician assistants, and pharmacists interested in the treatment of breast cancer are also invited to attend.

Conference Agenda: Topics Will Include: Which patients do not benefit from adjuvant chemotherapy? Emerging data on optimal adjuvant chemotherapy regimens What is the optimal duration of endocrine therapy? Management implications of the evolving genomic and biologic subsets of breast cancer Integration of HER2-targeted agents into adjuvant or neoadjuvant therapy, including the patient selection criteria Incorporating preoperative chemotherapy into treatment with surgery and radiation therapy Adjuvant ovarian suppression/ablation in premenopausal patients Role of PET scanning in early-stage breast cancer Novel therapeutic approaches to basal-like breast cancer

Registration Information: * INDUSTRY is defined by PER as any person employed by a for-profit organization, including biotech, financial, and pharmaceutical. Industry registrations cannot be processed on-line. To request attendance at a Congress, registrations can be submitted via fax, phone or e-mail. For more information e-mail us at CME@pergrouplp.com. A cancellation fee of 25% will be assessed on refunds requested prior to September 3, 2008, and a 50% fee on requests made between September 3, 2008, and September 19, 2008. No refunds will be made after September 19, 2008. There is no charge for substitution.

Conference Fees: Before July 31, 2008 Physicians $220.00, Fellows, Nurses, Pharmacists, PAs $120.00, Industry*$895.00 Prices increase August 1st. 2008

Continuing Education: Yes. Physicians: Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This activity has been approved for AMA PRA Category 1 Credit™. Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.

Miscellany: www.cancerconferences.com